The Schall Law Firm Files Class Action Lawsuit Against BioAge Labs, Inc. for Securities Violations

LOS ANGELES, CA / ACCESS Newswire / January 23, 2025

The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against BioAge Labs, Inc. (“BioAge” or “the Company”) (NASDAQ:BIOA) for violations of the federal securities laws. Investors who purchased the Company’s securities pursuant and/or traceable to the Company’s initial public offering (“IPO”) conducted on September 26, 2024, are encouraged to contact the firm before March 10, 2025.

This lawsuit stems from allegations that BioAge Labs, Inc. made materially false and misleading statements regarding its financial health and prospects to investors. The lawsuit claims that the company failed to disclose certain information that, once revealed, caused the stock price to plummet.

How This May Affect You

If you are an investor who purchased BioAge Labs, Inc. securities during the specified period, you may be eligible to participate in the class action lawsuit. By contacting The Schall Law Firm before March 10, 2025, you can learn more about your rights and potential options for recovery.

How This May Affect the World

Class action lawsuits against companies for securities violations help to hold corporations accountable and protect investors from fraudulent practices. This lawsuit against BioAge Labs, Inc. may set a precedent for transparency and disclosure requirements in the financial markets, ultimately benefiting investors worldwide.

Conclusion

It is crucial for investors to be aware of their rights and options in cases of alleged securities violations. The class action lawsuit filed by The Schall Law Firm against BioAge Labs, Inc. serves as a reminder of the importance of due diligence and transparency in the financial markets. By seeking justice and accountability, investors can help maintain integrity and trust in the securities industry.